Physician profile
Mark Daniel Cagle
NPI 1255950127
$3,400.32
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $617 · 2022: $897 · 2023: $1,049 · 2024: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $423.95 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $353.67 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $340.38 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.38 | 2022-2023 | Jardiance |
| Glaxosmithkline, LLC. | $250.86 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $227.90 | 2021-2024 | |
| Lilly USA, LLC | $198.05 | 2021-2024 | Mounjaro, Jardiance, Baqsimi |
| Gilead Sciences, INC. | $154.51 | 2021 | |
| Amgen INC. | $100.44 | 2023-2024 | Repatha, Otezla, Krystexxa |
| Lundbeck LLC | $87.26 | 2023-2024 | Rexulti |
| Lucid Diagnostics INC. | $86.19 | 2021-2023 | |
| Exact Sciences Corporation | $84.03 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $78.99 | 2021-2024 | |
| Boston Scientific Corporation | $78.48 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $70.91 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $70.10 | 2024 | Octrode, Freestyle Libre 3, Armada |
| Almatica Pharma LLC | $69.40 | 2021-2024 | Loreev Xr |
| Amarin Pharma, INC. | $60.12 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.32 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $36.62 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.89 | 2022-2023 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $25.89 | 2021 | |
| Impel Pharmaceuticals INC. | $23.52 | 2022 | |
| Idorsia Pharmaceuticals US INC | $23.26 | 2022 | |
| Sunovion Pharmaceuticals INC. | $22.42 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $21.66 | 2022 | |
| Nestle Healthcare Nutrition INC. | $21.49 | 2022 | |
| Antares Pharma, INC. | $20.29 | 2022 | |
| Impulse Dynamics (USA) INC. | $18.93 | 2024 | Optimizer |
| Sanofi-Aventis U.S. LLC | $18.06 | 2022 | |
| Nalu Medical, INC. | $17.07 | 2024 | Nalu Neurostimulation System |
| Merck Sharp & Dohme LLC | $16.81 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.47 | 2023 | Seglentis, Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.